Daily Bio News Summary — 2026-10-06: A deal-heavy Tuesday led by GE HealthCare, Novartis, and Shionogi

Tuesday’s file adds 68 news items compiled from public sources, dated 2026-09-11 through 2026-10-06 and heavily weighted toward the last two days. The batch is larger than a typical daily increment because a fuller sweep of the eleven tracked industry outlets picked up a set of late-September items that earlier runs had not captured; roughly half of the file is dated October 5–6.

Deal news dominates, but the day is not one-sided. Clinical readouts, a first-line cancer win, a handful of regulatory actions, manufacturing and platform build-outs, and a steady stream of early-stage financings all appear. No new company profiles were needed: every company named in a headline here already has a profile in the collection, and the seven companies carrying a companyId in this batch (AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Novartis, Roche, Sanofi) are all existing profiles.

One caveat up front: one tracked outlet again rendered as subscription-gated bodies and contributed nothing to the final set, and a second outlet’s article pages would not render at all, so its stories are absent rather than missed. Where a gated outlet’s story was also carried by a free source, the free version is in the file.

Deal flow: radiopharma, RNA, and rare disease

The single largest cash headline is GE HealthCare’s $945M acquisition of Sofie Biosciences, a radiopharmaceuticals move (BioPharma Dive, 2026-10-06) — an imaging incumbent buying deeper into the isotope supply chain that underpins the radioligand therapy boom.

Close behind in headline value, Novartis has committed almost $8B to a Chinese biotech’s RNA drugs (BioPharma Dive, 2026-10-06), the day’s clearest signal that large-cap partnering with China-based platforms is now routine rather than exceptional. A second Novartis item the same day — tapping China’s Abogen for an autoimmunity T-cell engager (Pharmaphorum, 2026-10-06) — reinforces the pattern rather than contradicting it.

In rare disease, Shionogi is paying $2B for IntraBio (BioSpace, 2026-10-06; Fierce Pharma, 2026-10-05), which takes the Japanese anti-infectives house further into neurology-adjacent commercial assets. Related smaller moves include CSL’s deal worth up to $1.6 billion with Swiss firm Alentis (Reuters, 2026-10-06), Novo’s payment of up to $2.6B to Hengrui for a once-weekly obesity pill (BioPharma Dive, 2026-09-29), Lilly deepening its Gate alliance with more than $870M in biobucks (BioSpace, 2026-10-05), and AstraZeneca taking a stake in Summit Therapeutics in a $2bn deal (Pharmaphorum, 2026-10-06; BioPharma Dive, 2026-09-11). Sanofi and Regeneron are broadening their alliance in the hunt for their next Dupixent (BioPharma Dive, 2026-09-29).

The pattern across the day: milestone-heavy, risk-shared structures, immunology and obesity assets, and China-based platforms on the other side of the table. Headline totals are ceilings, not cash on the table.

Clinical: a first-line lymphoma win and a mixed data slate

The most consequential readout is AbbVie and Genmab’s Epkinly setting what the headline calls a “new standard of care” in first-line lymphoma in Phase 3 (BioSpace, 2026-10-06; Fierce Pharma, 2026-10-06) — a bispecific moving earlier in the treatment sequence and, if it holds, redrawing front-line DLBCL economics.

Elsewhere the data was mixed rather than uniform:

• Pfizer’s eczema drug cleared skin in a mid-stage trial (BioPharma Dive, 2026-10-05), and separately Pfizer’s vitiligo Phase 3 data pave the way for FDA and EMA submissions (MedCity News, 2026-10-01).
• Vaxcyte’s pneumococcal vaccine exceeded expectations (Pharmaphorum, 2026-10-06) — after a difficult stretch for the program.
• UniQure tumbled on its latest Huntington’s gene therapy data (BioPharma Dive, 2026-09-29).
• Bristol Myers trial revisions shook confidence in a new class of fibrosis drugs (BioPharma Dive, 2026-09-29).
• Kodiak skyrocketed on positive study data for two eye drugs (BioPharma Dive, 2026-09-11).
• Mimetic’s peptide showed promise in reducing neuropathic pain (Fierce Biotech, 2026-10-06), and Vial dosed its first asthma patient in a Phase 1b study of an IL-13 x TSLP bispecific (PR Newswire, 2026-10-05).

Beam is suing two biotechs over alleged theft of base editing trade secrets (BioPharma Dive, 2026-09-29) — a reminder that platform IP is being litigated as hard as it is licensed.

Regulatory: a review opened, a review delayed, a first-in-class clearance

The FDA has started its review of Roche’s multiple sclerosis pill (BioPharma Dive, 2026-09-29), while the agency extended its review of Novo’s hemophilia A drug over manufacturing issues (BioSpace, 2026-10-06) — the classic split between a pipeline advancing and a filing slipping.

On the approval side, the FDA cleared the first drug for MCT8 deficiency (Pharmaphorum, 2026-10-06) — a rare-disease first — and AbbVie’s Cerevel takeover has delivered a Parkinson’s approval (Pharmaphorum, 2026-10-06), validating that acquisition. Device and diagnostics clearances round out the file: AIRS Medical received 510(k) clearance for SwiftSight body composition (PR Newswire, 2026-10-05), and OXOS Medical won a BARDA contract worth up to $24M (PR Newswire, 2026-10-06).

Also worth flagging: proposed nuclear safety rules threaten Novartis’s Pluvicto expansion (Fierce Pharma, 2026-10-06) — the regulatory bottleneck for radioligand therapies is now the isotope and facility regime, not the clinical data.

Manufacturing, platforms, and capital

The build-out continues. AstraZeneca cut the ribbon on a new R&D facility in Massachusetts (Pharmaphorum, 2026-10-06) and its Kendall Square center is framed as central to what the company hopes are “amazing things” (Fierce Biotech, 2026-10-06). Swiss CDMOs and CROs are riding a new wave of growth amid surging global demand (BioSpace, 2026-10-05).

On the platform side, an AI agent made a small drug R&D mistake and then kept going (BioPharma Dive, 2026-10-06) — a short but pointed case study on autonomy in discovery workflows — while the UK backed all health AI proposals in a commission report (Pharmaphorum, 2026-10-06) and a study found three in four FDA authorizations of AI medical devices were in radiology (PR Newswire, 2026-10-06). Veeva’s data quality suite crossed one million subjects across more than 1,000 studies (PR Newswire, 2026-10-06) and Gilead rolled out disease-specific wellness tooling with the Calm app (Fierce Pharma, 2026-10-05).

Capital formation is still open: Forbion raised a landmark €2.3B fund (Fierce Biotech, 2026-10-06), Varda raised $251M to make medicines in space (BioSpace, 2026-10-02), and the Fierce Biotech fundraising tracker logged KymaThera and RougeTx among the week’s rounds (Fierce Biotech, 2026-10-06). The counterweight: two Massachusetts biotechs called it quits (BioSpace, 2026-10-05), and a Q4 job-search piece argues urgency and flexibility are the keys (BioSpace, 2026-10-01). Roivant entered its commercial era with Lisraya (BioSpace, 2026-10-05), Kyverna nears market amid a fresh look at CAR-T risk in autoimmune disease (BioSpace, 2026-10-05), and Genentech marked its 50th anniversary with a documentary (Fierce Pharma, 2026-10-06).

What this batch is NOT telling us

• No mega-round in AI-native drug discovery. The AI items here are operational or regulatory (an agent’s error, a national strategy, device authorizations), not the platform mega-financings that have defined earlier batches.
• No priced IPOs. The one IPO item in the day’s raw set came from a gated outlet and is absent; the file contains financings and funds, not listings.
• No Phase 3 wins beyond the lymphoma bispecific. The remaining clinical items are Phase 1/2 or early-readout data, and several lean negative.
• No earnings or guidance. This is a news file, not a financials file.
• Nothing from the two outlets that returned gated or non-rendering pages. Their exclusive stories of the day are genuinely missing.

Reading order

1. GE HealthCare / Sofie Biosciences, $945M — the day’s largest cash deal and a read on radiopharma consolidation.
2. AbbVie & Genmab’s Epkinly first-line Phase 3 win — the item most likely to move a standard of care.
3. Shionogi / IntraBio, $2B — rare-disease commercial consolidation.
4. Novartis / Abogen, ~$8B — the China-platform partnership trend in one headline.
5. FDA clears first drug for MCT8 deficiency — a rare-disease first-in-class.

How to read the underlying articles

Each item below corresponds to a markdown file in the src/content/news/ folder of this site. Every file carries a sourceUrl field pointing at the original public article, plus sourceName, pubDate, category, and tags. Nothing in this summary goes beyond those frontmatter fields: deal values, phase labels, and program names are quoted from the headlines as published, not re-derived.

The full batch (68 items)

Deals, financings, and corporate moves

1. GE HealthCare to acquire Sofie Biosciences for $945M — BioPharma Dive, 2026-10-06
2. Novartis wagers almost $8B on a Chinese biotech’s RNA drugs — BioPharma Dive, 2026-10-06
3. Shionogi makes $2B rare disease play with IntraBio buy — BioSpace, 2026-10-06
4. Shionogi acquires IntraBio to bolster rare disease business — Fierce Pharma, 2026-10-05
5. Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition — MedCity News, 2026-10-01
6. CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis — Reuters Biopharma, 2026-10-06
7. Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill — BioPharma Dive, 2026-09-29
8. Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks — BioSpace, 2026-10-05
9. AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push — BioPharma Dive, 2026-09-11
10. AZ takes stake in Summit Therapeutics in $2bn deal — Pharmaphorum, 2026-10-06
11. Sanofi, Regeneron broaden alliance to find their next Dupixent — BioPharma Dive, 2026-09-29
12. Novartis taps China’s Abogen for autoimmunity TCE — Pharmaphorum, 2026-10-06
13. Forbion’s ‘landmark’ €2.3B fundraise to benefit 30 biotechs — Fierce Biotech, 2026-10-06
14. Varda raises $251M to leverage gravity in space for drug production — BioSpace, 2026-10-02
15. Fierce Biotech Fundraising Tracker ’26: KymaThera, RougeTx & more — Fierce Biotech, 2026-10-06
16. Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya — BioSpace, 2026-10-05
17. 2 Massachusetts biotechs call it quits — BioSpace, 2026-10-05
18. Introducing Fierce Biotech’s 2026 Fierce 15 — Fierce Biotech, 2026-10-05
19. BioSpace 40 Under 40 winners make their mark on biopharma — BioSpace, 2026-10-05
20. Urgency, flexibility during Q4 job search among keys to success — BioSpace, 2026-10-01

Clinical and preclinical data 21. AbbVie, Genmab’s Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3 — BioSpace, 2026-10-06 22. AbbVie and Genmab’s Epkinly combo scores first-line DLBCL win — Fierce Pharma, 2026-10-06 23. Pfizer’s eczema drug clears skin in mid-stage trial — BioPharma Dive, 2026-10-05 24. Pfizer Pill’s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions — MedCity News, 2026-10-01 25. Vaxcyte’s pneumococcal jab exceeds expectations — Pharmaphorum, 2026-10-06 26. UniQure tumbles with latest data for Huntington’s gene therapy — BioPharma Dive, 2026-09-29 27. Bristol Myers trial revisions shake confidence in new class of fibrosis drugs — BioPharma Dive, 2026-09-29 28. Kodiak skyrockets on positive study data for 2 eye drugs — BioPharma Dive, 2026-09-11 29. Mimetic’s peptide shows promise in reducing neuropathic pain — Fierce Biotech, 2026-10-06 30. Vial Doses First Patient with Asthma in Phase 1b Study of Vial’s IL-13 x TSLP Bispecific — PR Newswire, 2026-10-05 31. Beam sues 2 biotechs, alleging theft of base editing trade secrets — BioPharma Dive, 2026-09-29 32. In this hospital, pulse oximeters went from overestimating to underestimating blood oxygen — STAT News, 2026-10-06 33. What are hospital longevity programs, and what can they tell you about your health? — STAT News, 2026-10-06 34. ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’ — BioPharma Dive, 2026-09-11 35. Immunology Startup ai3Bio Aims to Redefine What It Means to Reset the Immune System — MedCity News, 2026-10-01 36. Weighing the risks of CAR T in autoimmune disease as Kyverna nears market — BioSpace, 2026-10-05 37. How NIH’s Kleinstreuer reduces animal tests without ‘backlash’ — Fierce Biotech, 2026-10-06 38. Kairos seizes moment to push cancer asset into earlier setting — Fierce Biotech, 2026-10-06

Regulatory and FDA actions 39. FDA starts review of Roche’s multiple sclerosis pill — BioPharma Dive, 2026-09-29 40. FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues — BioSpace, 2026-10-06 41. FDA clears first drug for MCT8 deficiency — Pharmaphorum, 2026-10-06 42. AbbVie’s Cerevel takeover delivers Parkinson’s approval — Pharmaphorum, 2026-10-06 43. Proposed nuclear rules threaten Novartis’ Pluvicto — Fierce Pharma, 2026-10-06 44. AIRS Medical Receives FDA 510(k) Clearance for SwiftSight Body Composition — PR Newswire, 2026-10-05 45. OXOS Medical Awarded BARDA Contract Worth Up to $24 Million — PR Newswire, 2026-10-06 46. Three in Four FDA Authorizations of AI Medical Devices Were in Radiology — PR Newswire, 2026-10-06 47. Lilly’s Jaypirca (pirtobrutinib) receives an additional approval — PR Newswire, 2026-10-02 48. Zydus, MSN partner to Launch First Generic of Adempas (Riociguat Tablets) in the U.S. — PR Newswire, 2026-10-05 49. PRM Pharma and Ingenus Pharmaceuticals Announce Orange Book Listing of Patent — PR Newswire, 2026-10-05 50. HAI Solutions Issued U.S. Patent for RFID-Enabled QIKcap Platform — PR Newswire, 2026-10-05

Manufacturing, platforms, and commercial 51. AstraZeneca cuts ribbon on new R&D facility in Massachusetts — Pharmaphorum, 2026-10-06 52. AZ hopes for ‘amazing things’ from Kendall Square R&D center — Fierce Biotech, 2026-10-06 53. Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand — BioSpace, 2026-10-05 54. An AI agent made a tiny drug R&D mistake. Then it kept going. — BioPharma Dive, 2026-10-06 55. UK backs all health AI proposals in commission report — Pharmaphorum, 2026-10-06 56. Veeva DQS Cleans Data for More Than 1 Million Subjects Across Over 1,000 Studies — PR Newswire, 2026-10-06 57. Gilead rolls out disease-specific wellness tools with Calm app — Fierce Pharma, 2026-10-05 58. Genentech opens its history books in 50 year anniversary doc — Fierce Pharma, 2026-10-06 59. AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll — BioSpace, 2026-09-30 60. 3 takeaways from a European obesity scientific meeting — BioPharma Dive, 2026-10-05 61. Lilly, Foghorn part ways; Wave’s FDA-approved plans — BioPharma Dive, 2026-10-05 62. Emboline Announces First U.S. Commercial Use of the Emboliner Embolic Protection System — PR Newswire, 2026-10-02 63. ZEISS demonstrates new digital and visual enhancements across ophthalmic workflows — PR Newswire, 2026-10-06 64. Cala Announces Nationwide Launch of its Next Generation TAPS Therapy Wearable — PR Newswire, 2026-10-06 65. Once-daily RELEXXII (methylphenidate hydrochloride extended-release tablet) — PR Newswire, 2026-10-06 66. Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X — PR Newswire, 2026-10-06 67. Headlands Research - Summit Portland Celebrates 50 Years of Advancing Alzheimer’s and CNS Clinical Research — PR Newswire, 2026-10-06 68. Talkiatry Earns Joint Commission Accreditation for Behavioral Health Care — PR Newswire, 2026-10-05